CN113702561A - Method for detecting chiral polypeptide drug diastereoisomer impurities - Google Patents
Method for detecting chiral polypeptide drug diastereoisomer impurities Download PDFInfo
- Publication number
- CN113702561A CN113702561A CN202110968613.4A CN202110968613A CN113702561A CN 113702561 A CN113702561 A CN 113702561A CN 202110968613 A CN202110968613 A CN 202110968613A CN 113702561 A CN113702561 A CN 113702561A
- Authority
- CN
- China
- Prior art keywords
- phase
- detection
- polypeptide drug
- impurities
- diastereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 229940079593 drug Drugs 0.000 title claims abstract description 40
- 239000012535 impurity Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000010828 elution Methods 0.000 claims abstract description 17
- 239000000523 sample Substances 0.000 claims abstract description 15
- 239000012488 sample solution Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims abstract description 8
- 230000005526 G1 to G0 transition Effects 0.000 claims abstract description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 13
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 13
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 13
- -1 [ (S) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidin-3-yl ] borate salt Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 5
- 108020001588 κ-opioid receptors Proteins 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 3
- 108010093625 Opioid Peptides Proteins 0.000 description 3
- 102000001490 Opioid Peptides Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000003399 opiate peptide Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 108700023159 delta Opioid Receptors Proteins 0.000 description 2
- 102000048124 delta Opioid Receptors Human genes 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/89—Inverse chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a method for detecting chiral polypeptide drug diastereoisomer impurities, which comprises the following steps: s1) dissolving the polypeptide drug sample and filtering to prepare a detection sample solution; s2) adopting a reversed phase chromatography, taking octadecylsilane chemically bonded silica as a stationary phase, taking an inorganic salt water solution as an A phase and taking methanol or acetonitrile as a B phase, and carrying out gradient elution on the detection sample solution to realize the separation of diastereoisomer impurities and main components. The reversed phase chromatographic analysis method mainly solves the problems that the conventional analysis method cannot effectively detect the diastereoisomer impurities and accurately perform qualitative and quantitative detection on the medicine, and provides a detection means guarantee for effectively controlling related substances of the product and monitoring the quality level of the product.
Description
Technical Field
The invention relates to the technical field of detection, in particular to a method for detecting chiral polypeptide drug diastereoisomer impurities.
Background
Opioid receptors are a major class of G protein-coupled receptors, are endogenous opioid peptides and opioid drug binding targets, and are widely found in the central and peripheral nervous systems. Opioid receptors, which are activated to regulate the immune and endocrine systems of the nervous system, are the most powerful and commonly used central analgesics. Endogenous opioid peptides are naturally occurring opioid active substances in mammals, and currently known endogenous opioid peptides are broadly classified into several classes, namely enkephalins, endorphins, dynorphins and neorphins. Its corresponding opioid receptors, i.e., μ, δ and κ receptors, are present in the central nervous system. Mu receptor has the strongest analgesic activity and the strongest addiction, and is the main reason for generating side effects. The delta receptor has small addiction and also has unobvious analgesic effect. Kappa receptor (KOR) analgesic activity is intermediate between the first two. The polypeptide KOR agonist can exert analgesic effect in periphery without entering into center, and has no adverse side effects such as respiratory depression and constipation, and lower addiction, thus having potential of drug addiction treatment.
Patent CN111233974B reports a series of novel KOR agonists with excellent agonistic activity, including a compound represented by the structural formula I-1 (chemical name: [ (S) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidin-3-yl ] boronic acid hydrochloride). The crude product of the compound I-1 contains various process impurities, degradation impurities and chiral isomer impurities (formula I-2, chemical name: [ (R) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidine-3-yl ] boric acid hydrochloride) which are difficult to separate, the polarity difference of the isomer impurities and the main component is very small, the physicochemical properties are extremely similar, the isomer impurities are extremely difficult to be effectively separated in HPLC detection, great challenges are brought to detection and analysis, and samples meeting clinical requirements cannot be effectively monitored and guided to be produced. Therefore, developing a simple, convenient, reproducible, stable and reliable analysis method to monitor the impurities, especially chiral diastereomer impurities, to ensure the quality controllability in the process of drug development is a problem to be solved at present.
Disclosure of Invention
In view of the above, the technical problem to be solved by the present invention is to provide a method for detecting diastereomer impurities of chiral polypeptide drugs, which can effectively detect diastereomer impurities that cannot be detected under conventional detection conditions by reasonably optimizing chromatographic conditions, thereby providing an effective monitoring means for ensuring the quality level of the polypeptide drugs.
In order to achieve the above purpose, the invention provides a method for detecting chiral polypeptide drug diastereoisomer impurities, which comprises the following steps:
s1) dissolving the polypeptide drug sample and filtering to prepare a detection sample solution;
s2) adopting a reversed phase chromatography, taking octadecylsilane chemically bonded silica as a stationary phase, taking an inorganic salt water solution as an A phase and taking methanol or acetonitrile as a B phase, and carrying out gradient elution on the detection sample solution to realize the separation of diastereoisomer impurities and main components.
The invention adopts HPLC reversed phase chromatography to detect the diastereoisomer impurities, provides an effective monitoring means, can accurately perform qualitative and quantitative analysis on the medicament, and effectively ensures the quality of the chiral polypeptide medicament.
In the invention, the polypeptide drug is a crude [ (S) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidine-3-yl ] borate (shown as the formula I-1), wherein the crude [ (R) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidine-3-yl ] borate impurity (shown as the formula I-2) is contained.
The polypeptide drug is a polypeptide compound obtained by a solid phase or liquid phase synthesis method.
In a preferred embodiment of the present invention, the solvent in which the polypeptide drug sample is dissolved is a polar hydrophilic solvent. Further preferably one or more of water, methanol, ethanol, and acetonitrile. More preferably methanol, water or a mixture of both.
The solubility of the polypeptide drug sample in the polar hydrophilic solvent is from soluble to very soluble.
Preferably, the concentration of the detection sample solution is less than or equal to 5 mg/ml. More preferably 0.5 to 1 mg/ml.
The method adopts the reversed phase chromatography to carry out gradient elution on the detection sample solution, thereby realizing the separation of the diastereoisomer impurities and the main component.
The reverse phase chromatographic column is preferably a reverse phase C18 liquid chromatographic column or other column equivalent chromatographic column. More preferably a YMC-Pack ODS-AQ or Aeris TM PEPTIDE XB-C18 column. Further preferred is YMC-Pack ODS-AQ, 4.6 x 150mm, 3 μm or Aeris TM PEPTIDE XB-C18 liquid chromatography column (4.6X 250mm, 3.6 μm).
Preferably, the phase A is an aqueous solution of ammonium sulfate.
The concentration of the ammonium sulfate aqueous solution is preferably 5 mM-20 mM; more preferably 5 mM.
The pH value of the ammonium sulfate aqueous solution is preferably 1.5-2.5, and more preferably 2.0-2.5.
The pH value of the ammonium sulfate aqueous solution is preferably adjusted by using sulfuric acid.
In the present invention, the phase B is preferably methanol or acetonitrile, and more preferably methanol.
In a preferred embodiment of the present invention, the conditions of the reverse phase chromatography are:
the flow rate is 0.8-1.2 ml/min; the column temperature is 30-45 ℃; the detection wavelength is 220 nm; the sample volume is 10-100 μ l.
The flow rate is further preferably 0.8, 1.0 or 1.2 ml/min; most preferably 1.0 ml/min.
The column temperature is further preferably 35 to 45 ℃, and most preferably 45 ℃.
The detection wavelength is preferably 220 nm.
The sample injection amount is further preferably 10 to 20 mu l.
In some embodiments of the invention, the chromatographic conditions are as shown in table 1:
table 1 chromatographic conditions of the invention
Preferably, the gradient elution is specifically as follows:
maintaining 75% of phase A in 0-10min, reducing phase A from 75% to 70% in 10.01-25 min, reducing phase A from 70% to 68% in 25.01-35 min, reducing phase A from 68% to 50% in 35.01-55 min, maintaining phase A to 65min, and recovering 75% of mobile phase A from 65.01 min-75 min to perform chromatographic column balance.
The invention develops a detection method of diastereoisomers which only belongs to chiral polypeptide drugs through a large amount of experimental investigation. The experimental result shows that in the detection map obtained by the detection method, the retention time (RRT) of the diastereoisomer impurities in front of the main component medicament relative to the chiral polypeptide medicament is about 0.96.
Compared with the prior art, the invention provides a method for detecting chiral polypeptide drug diastereoisomer impurities, which comprises the following steps: s1) dissolving the polypeptide drug sample and filtering to prepare a detection sample solution; s2) adopting a reversed phase chromatography, taking octadecylsilane chemically bonded silica as a stationary phase, taking an inorganic salt water solution as an A phase and taking methanol or acetonitrile as a B phase, and carrying out gradient elution on the detection sample solution to realize the separation of diastereoisomer impurities and main components. The reversed phase chromatographic analysis method mainly solves the problems that the conventional analysis method cannot effectively detect the diastereoisomer impurities and accurately perform qualitative and quantitative detection on the medicine, and provides a detection means guarantee for effectively controlling related substances of the product and monitoring the quality level of the product.
Drawings
FIG. 1 is a conventional HPLC profile of crude polypeptide drug;
FIG. 2 is a HPLC analysis detection profile of example 1;
FIG. 3 is a HPLC analysis detection profile of example 2;
FIG. 4 is a HPLC analysis detection map of comparative example 1;
FIG. 5 is a HPLC analysis detection map of comparative example 2.
Detailed Description
In order to further illustrate the present invention, the following examples are provided to describe the detection method of the chiral polypeptide drug diastereomer impurity.
The following examples are prepared by the method disclosed in patent CN111233974B example 2.
Example 1
A method for detecting diastereoisomers of a chiral polypeptide drug, comprising:
(1) test solution: taking 50mg of the crude chiral polypeptide drug, adding water to dissolve and dilute the crude chiral polypeptide drug to prepare a solution containing about 0.5mg of the crude chiral polypeptide drug in each 1ml, shaking up the solution, and filtering the solution by using a 0.22um organic filter membrane to obtain a crude filtrate for later use.
(2) Chromatographic conditions are as follows: using YMC-Pack ODS-AQ, 4.6 x 150mm, 3 μm column; taking ammonium sulfate buffer solution (5mmol/L ammonium sulfate, pH adjusted to 2.5 with sulfuric acid) as mobile phase A and methanol as mobile phase B, performing gradient elution according to the following table, with flow rate of 1.0 ml/min; the column temperature is 45 ℃; the detection wavelength is 220 nm; the amount of the sample was 20. mu.l.
(3) The assay was run at the following gradient 2:
table 2 example 1 gradient elution conditions
FIG. 1 is a conventional HPLC chromatogram of a crude polypeptide drug, and it can be seen that chiral diastereomers and the main peaks overlap.
The HPLC analysis detection spectrum of the embodiment is shown in figure 2, the retention time of the main component is 104.273min, and the retention time of the chiral diastereoisomer impurity is 98.000 min. Through calculation: the diastereomeric impurities of this example were able to be separated efficiently from the main component with a degree of separation of 1.46.
Example 2
A method for detecting diastereoisomers of a chiral polypeptide drug, comprising:
(1) test solution: taking 50mg of the crude chiral polypeptide drug, adding water to dissolve and dilute the crude chiral polypeptide drug to prepare a solution containing about 0.5mg of the crude chiral polypeptide drug in each 1ml, shaking up the solution, and filtering the solution by using a 0.22um organic filter membrane to obtain a crude filtrate for later use.
(2) Chromatographic conditions are as follows: an Aeris PEPTIDE XB-C18 liquid chromatography column (4.6X 250mm, 3.6 μm) was used; taking ammonium sulfate buffer solution (5mmol/L ammonium sulfate, pH adjusted to 2.2 with sulfuric acid) as mobile phase A and methanol as mobile phase B, performing gradient elution according to the following table, with flow rate of 1.0 ml/min; the column temperature is 45 ℃; the detection wavelength is 220 nm; the amount of the sample was 20. mu.l.
(3) The assay was run at the following gradient 3:
table 3 example 2 gradient elution conditions
Through calculation: the diastereomeric impurities of this example were able to be separated completely and effectively from the main component with a degree of separation of 1.45.
The HPLC analysis detection spectrum is shown in figure 3.
Comparative example 1
A method for detecting diastereoisomers of a chiral polypeptide drug, comprising:
(1) test solution: taking 50mg of the crude chiral polypeptide drug, adding water to dissolve and dilute the crude chiral polypeptide drug to prepare a solution containing about 0.5mg of the crude chiral polypeptide drug in each 1ml, shaking up the solution, and filtering the solution by using a 0.22um organic filter membrane to obtain a crude filtrate for later use.
(2) Chromatographic conditions are as follows: using an AQ-C18 liquid chromatography column (4.6X 250mm, 5 μm); taking ammonium chloride buffer solution (10mmol/L ammonium sulfate, pH adjusted to 2.5 with hydrochloric acid) as mobile phase A and methanol as mobile phase B, performing gradient elution according to the following table, with flow rate of 1.0 ml/min; the column temperature is 40 ℃; the detection wavelength is 220 nm; the amount of the sample was 10. mu.l.
(3) Detection, run at the following gradient 4:
TABLE 4 comparative example 1 gradient elution conditions
Through calculation: the detection method of the comparative example can detect diastereoisomer impurities, and obviously under the conditions that the elution gradient is not changed, and other chromatographic conditions such as only a mobile phase, a chromatographic column and the like are changed, the diastereoisomer impurities cannot be completely and effectively separated from the main component, the separation degree is only 1.0, and the accurate integration and quantification requirements cannot be realized.
The HPLC analysis detection spectrum is shown in figure 4.
Comparative example 2
A method for detecting diastereoisomers of a chiral polypeptide drug, comprising:
(1) test solution: taking 50mg of the crude chiral polypeptide drug, adding water to dissolve and dilute the crude chiral polypeptide drug to prepare a solution containing about 0.5mg of the crude chiral polypeptide drug in each 1ml, shaking up the solution, and filtering the solution by using a 0.22um organic filter membrane to obtain a crude filtrate for later use.
(2) Chromatographic conditions are as follows: a liquid chromatography column (4.6X 250mm, 5 μm) using DAISOPAK SP-ODS-P (C18); taking ammonium sulfate buffer solution (5mmol/L ammonium sulfate, pH adjusted to 2.5 with sulfuric acid) as mobile phase A and methanol as mobile phase B, performing gradient elution according to the following table, with flow rate of 1.2 ml/min; the column temperature is 30 ℃; the detection wavelength is 220 nm; the amount of the sample was 20. mu.l.
(3) Detection, run at gradient as in Table 5 below
TABLE 5 comparative example 2 gradient elution conditions
Through calculation: the detection method of the embodiment can detect diastereoisomer impurities, and obviously, under the conditions that the elution gradient and the mobile phase are not changed, and only other chromatographic conditions such as a chromatographic column, flow rate, column temperature and the like are changed, the diastereoisomer impurities cannot be completely and effectively separated from main components, the separation degree is only 0.7, and the requirements of accurate integration and quantification cannot be met.
The HPLC analysis detection spectrum is shown in figure 5.
The above description of the embodiments is only intended to facilitate the understanding of the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.
Claims (9)
1. A method for detecting chiral polypeptide drug diastereoisomer impurities comprises the following steps:
s1) dissolving the polypeptide drug sample and filtering to prepare a detection sample solution;
s2) adopting a reversed phase chromatography, taking octadecylsilane chemically bonded silica as a stationary phase, taking an inorganic salt water solution as an A phase and taking methanol or acetonitrile as a B phase, and carrying out gradient elution on the detection sample solution to realize the separation of diastereoisomer impurities and main components.
2. The assay of claim 1, wherein said polypeptide drug is a crude [ (S) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidin-3-yl ] borate salt comprising an impurity of [ (R) -1- (D-phenylalanyl-D-leucyl-D-lysyl) pyrrolidin-3-yl ] borate.
3. The method of claim 1, wherein the solvent in which the polypeptide drug sample is dissolved is a polar hydrophilic solvent.
4. The detection method according to claim 3, wherein the solvent in which the polypeptide drug sample is dissolved is selected from one or more of water, methanol, ethanol, and acetonitrile.
5. The detection method according to claim 3, wherein the concentration of the detection sample solution is 5mg/ml or less.
6. The detection method according to claim 1, wherein the phase A is an aqueous ammonium sulfate solution.
7. The detection method according to claim 6, wherein the concentration of the aqueous ammonium sulfate solution is 5mM to 20 mM; the pH value is 1.5-2.5.
8. The detection method according to claim 1, wherein the conditions of the reverse phase chromatography are:
the flow rate is 0.8-1.2 ml/min; the column temperature is 30-45 ℃; the detection wavelength is 220 nm; the sample volume is 10-100 μ l.
9. The detection method according to claim 1, wherein the gradient elution is in particular:
maintaining 75% of phase A in 0-10min, reducing phase A from 75% to 70% in 10.01-25 min, reducing phase A from 70% to 68% in 25.01-35 min, reducing phase A from 68% to 50% in 35.01-55 min, maintaining phase A to 65min, and recovering 75% of mobile phase A from 65.01 min-75 min to perform chromatographic column balance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110968613.4A CN113702561B (en) | 2021-08-23 | 2021-08-23 | Method for detecting diastereoisomeric impurities of chiral polypeptide drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110968613.4A CN113702561B (en) | 2021-08-23 | 2021-08-23 | Method for detecting diastereoisomeric impurities of chiral polypeptide drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113702561A true CN113702561A (en) | 2021-11-26 |
| CN113702561B CN113702561B (en) | 2024-03-22 |
Family
ID=78654075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110968613.4A Active CN113702561B (en) | 2021-08-23 | 2021-08-23 | Method for detecting diastereoisomeric impurities of chiral polypeptide drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113702561B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1664108A1 (en) * | 2003-08-21 | 2006-06-07 | Novo Nordisk A/S | Separation of polypeptides comprising a racemized amino acid |
| CN106290601A (en) * | 2015-06-29 | 2017-01-04 | 深圳翰宇药业股份有限公司 | Aminoacid racemization and the detection method of diastereomer impurity in polypeptide drugs |
| CN107290438A (en) * | 2016-03-31 | 2017-10-24 | 深圳翰宇药业股份有限公司 | A kind of HPLC analytical method of polypeptide about material |
| CN110658289A (en) * | 2019-10-25 | 2020-01-07 | 苏州强耀生物科技有限公司 | Purification method of RGD peptide containing multiple cysteines |
| CN110702819A (en) * | 2019-11-08 | 2020-01-17 | 浙江美测医药科技有限公司 | Method for separating and measuring polypeptide chiral isomers containing multiple chiral centers by using high performance liquid chromatography |
| CN111505161A (en) * | 2020-05-11 | 2020-08-07 | 成都市科隆化学品有限公司 | Method for detecting enantiomer of protected amino acid |
-
2021
- 2021-08-23 CN CN202110968613.4A patent/CN113702561B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1664108A1 (en) * | 2003-08-21 | 2006-06-07 | Novo Nordisk A/S | Separation of polypeptides comprising a racemized amino acid |
| CN106290601A (en) * | 2015-06-29 | 2017-01-04 | 深圳翰宇药业股份有限公司 | Aminoacid racemization and the detection method of diastereomer impurity in polypeptide drugs |
| CN107290438A (en) * | 2016-03-31 | 2017-10-24 | 深圳翰宇药业股份有限公司 | A kind of HPLC analytical method of polypeptide about material |
| CN110658289A (en) * | 2019-10-25 | 2020-01-07 | 苏州强耀生物科技有限公司 | Purification method of RGD peptide containing multiple cysteines |
| CN110702819A (en) * | 2019-11-08 | 2020-01-17 | 浙江美测医药科技有限公司 | Method for separating and measuring polypeptide chiral isomers containing multiple chiral centers by using high performance liquid chromatography |
| CN111505161A (en) * | 2020-05-11 | 2020-08-07 | 成都市科隆化学品有限公司 | Method for detecting enantiomer of protected amino acid |
Non-Patent Citations (1)
| Title |
|---|
| 康建磊等: "关于合成多肽药物中非对映异构体杂质的研究", 《中国现代应用药学》, vol. 27, no. 5, pages 387 - 389 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113702561B (en) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Msagati et al. | Comparative study of sample preparation methods; supported liquid membrane and solid phase extraction in the determination of benzimidazole anthelmintics in biological matrices by liquid chromatography–electrospray–mass spectrometry | |
| CN113358804A (en) | Ion chromatography analysis method for determining genotoxic impurity nitrite in eltrombopag ethanolamine | |
| CN101685084B (en) | Method for detecting methylnaltrexone bromide and impurity thereof by chromatography | |
| CN104678026B (en) | Method for determining content of tetrabutylammonium bromide in organic medicine | |
| CN110687229A (en) | Diclofenac sodium raw material and analysis method of related substances in preparation thereof | |
| CN109444318A (en) | A kind of efficient liquid-phase chromatography method for analysis of bacillus peptide composition | |
| CN113702561A (en) | Method for detecting chiral polypeptide drug diastereoisomer impurities | |
| CN109239253B (en) | High performance liquid detection method for impurities of abacavir | |
| CN110927278A (en) | Improved method for separating imidapril hydrochloride related substances | |
| Yamamoto et al. | Novel methylcellulose-immobilized cation-exchange precolumn for on-line enrichment of cationic drugs in plasma | |
| CN104007185B (en) | A kind of HPLC assay methods for detecting impurity in zanamivir and preparation containing zanamivir | |
| Sato et al. | Weak cation-exchange restricted-access material for on-line purification of basic drugs in plasma | |
| Wenzl et al. | Determination and quantification of clonidine in human blood serum | |
| Cheng et al. | Rapid and reliable high-performance liquid chromatographic method for analysing human plasma serotonin, 5-hydroxyindoleacetic acid, homovanillic acid and 3, 4-dihydroxyphenylacetic acid | |
| Yang et al. | Enantioselective determination of trantinterol in rat plasma by ultra performance liquid chromatography–electrospray ionization mass spectrometry after derivatization | |
| CN104502499B (en) | A kind of efficient liquid phase detection method of isomeride | |
| CN108362789B (en) | High performance liquid chromatography detection method for abamectin sodium optical isomer | |
| Chang et al. | A Simple and Rapid High Performance Liquid Chromatographic Method with Fluorescence Detection for the Estimation of Amikacin in Plasma‐Application to Preclinical Pharmacokinetics | |
| CN102375044B (en) | Method for analyzing related substance from hydrochloric acid bendamustine intermediate Z6 | |
| Nielsen et al. | High-performance liquid chromatography of clomipramine and metabolites in human plasma and urine | |
| CN110554099A (en) | Method for analyzing impurity C, impurity D and enantiomer in palonosetron hydrochloride injection or bulk drug | |
| CN109406685B (en) | High performance liquid chromatography method for separating carfilzomib and isomers thereof | |
| Van Belle et al. | Narrow-bore liquid chromatographic assay for oxcarbazepine and its major metabolite in rat brain, liver and blood microdialysates | |
| CN101531601B (en) | Method for separating and analyzing dopexamine hydrochloride by using HPLC method | |
| CN107290453B (en) | The HPLC analysis method of palonosetron Hcl synthesis intermediate product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |